title: Visualizing the vitreous body in the anterior chamber using 11-deoxycortisol after posterior capsule rupture in an animal model.
abstract: OBJECTIVE
  To develop a new technique to visualize vitreous body prolapsed in the anterior chamber using 11-deoxycortisol.
  
  
  METHODS
  Experimental study.
  
  
  METHODS
  An animal model of posterior capsule rupture was developed to investigate the usefulness of 11-deoxycortisol, a precursor of cortisol without steroid activity. After the intentional creation of posterior capsule rupture, the suspension of 11-deoxycortisol was injected into the anterior chamber of rabbit eyes. After gentle irrigation and aspiration, the vitreous body that had prolapsed into the anterior chamber was removed using an anterior vitrectomy cutter. To investigate the safety of 11-deoxycortisol, the biomicroscopic appearance, intraocular pressure (IOP), corneal endothelial count, and microstructure of the corneal endothelium were examined in the rabbits that received injections of 11-deoxycortisol in the anterior chamber.
  
  
  RESULTS
  In our posterior capsule rupture model, the vitreous in the anterior chamber became clearly visible, with 11-deoxycortisol showing white particles entrapped on its surface. The injection of 11-deoxycortisol facilitated the complete removal of the vitreous body from the anterior chamber. In intact rabbit eyes, most of the injected 11-deoxycortisol had disappeared from the anterior chamber by 12 hours after injection. The injection of 11-deoxycortisol had no effect on IOP, corneal endothelial density, or the microstructure of the corneal endothelium.
  
  
  CONCLUSIONS
  The injection of 11-deoxycortisol in the anterior chamber is useful in visualizing the vitreous body and has no significant side effects. This technique might reduce the intraoperative and postoperative complications of anterior vitrectomy after posterior capsule rupture.
authors.affiliation: Department of Ophthalmology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan. yuichikaji@hotmail.com
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kaji
authors.forename: Takahiro
authors.initials: T
authors.lastname: Hiraoka
authors.forename: Fumiki
authors.initials: F
authors.lastname: Okamoto
authors.forename: Masaki
authors.initials: M
authors.lastname: Sato
authors.forename: Beihua
authors.initials: B
authors.lastname: Hu
authors.forename: Nayori
authors.initials: N
authors.lastname: Yamane
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Oshika
mesh_terms: D000818:Animals; D000867:Anterior Chamber / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D002452:Cell Count; D003350:Cortodoxone / Q000493:pharmacokinetics / Q000633:toxicity; D004195:Disease Models, Animal; D004728:Endothelium, Corneal / Q000473:pathology; D005128:Eye Diseases / Q000175:diagnosis*; D007429:Intraocular Pressure / Q000187:drug effects; D007431:Intraoperative Complications / Q000175:diagnosis*; D007903:Lens Capsule, Crystalline / Q000293:injuries*; D011183:Postoperative Complications / Q000175:diagnosis*; D011391:Prolapse; D011817:Rabbits; D012421:Rupture; D012449:Safety; D014822:Vitreous Body / Q000473:pathology*
chemical_list: D003350:Cortodoxone